The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement
NCT ID: NCT01112436
Last Updated: 2011-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
258 participants
INTERVENTIONAL
2010-05-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Total 258 patients will be randomized into one of two groups (groupC or groupI) based on Excel number generation.
Patients in group C will receive no medication intraoperatively, and patients in group I will receive oral oxycodone and celecoxib preoperatively and a periarticular injection of multi-drug regimen during operation.
Visual analogue scale pain scores, fentanyl consumption and the frequency at which patients pushed the button (FPB) of a patient-controlled analgesia system will be recorded at 1, 4, 7 postoperative day.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibiotic Prophylaxis in Primary Joint Arthroplasty of the Hip and Knee.
NCT03348254
Effect of Periprosthetic Fracture on Hip Function After Femoral Neck-preserving Total Hip Arthroplasty
NCT02981823
Effect of Peri-operative Glucocorticoids on Short-term Functional Outcome After THA
NCT04317872
Femoral BMD Change Following Cemented or Cementless Total Knee Arthroplasty
NCT06733597
Full Versus Partial Repairing of Soft Tissue Surrounding the Hip in Arthroplasty for Femoral Neck Fractures
NCT02897440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
And patients in group I will receive periarticular injection of 50 ml solution which contains ropivacaine 15 mg, epinephrine 0.3 mg, cefmetazole 1000mg, ketorolac 30 mg and morphine HCL 10mg before closure of surgical wound.
Patients in group C will receive no medication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group (group C)
control group will receive no medication preoperatively and during operation
none of medication preoperatively and intraoperatively
Patients in Group C wil receive none of medication preoperatively and intraoperatively
periarticular injecion group (group I)
patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
periarticular injection of multidrug regimen
periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
periarticular injection of multidrug regimen
periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
none of medication preoperatively and intraoperatively
Patients in Group C wil receive none of medication preoperatively and intraoperatively
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* partial hip replacement
Exclusion Criteria
* reoperation
* mental change
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chung-Ang University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yong Chan Ha, M.D. & Ph.D.
Role: STUDY_DIRECTOR
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Hyun Kang, M.D. & Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ChungAng University
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChunaAngUH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.